Fresenius Medical Care NYSE: FMS
Fresenius Medical Care Corp. is a Germany-based firm specializes in treatment and services for patients with chronic kidney failure
Name | Fresenius Medical Care |
Ticker | FMS |
Exchange | NYSE |
Sector | Health Care |
Industry | Kidney Failure |
Price
52W Low/High |
37.84
33.93 / 46.55 |
Momentum | Neutral |
Market cap | 23 B |
1Y Total Return |
9.14%
Weak |
1Y Volatility |
26.40%
Low Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Fresenius Medical Care Corp. is a Germany-based firm specializes in treatment and services for patients with chronic kidney failure
Details
Ticker | FMS |
Name | Fresenius Medical Care |
ISIN | DE0005785604 |
CUSIP | |
Exchange | NYSE |
Sector | Health Care |
Industry | Kidney Failure |
Country | Germany |
Currency | U.S. Dollar |
Share as of 4/13/21
Close Price | 37.84 |
52W Low/High | 33.93 / 46.55 |
Market cap | 23 B |
1Y Total Return |
9.14%
Weak |
1Y Volatility |
26.40%
Low Risk |
Beta | 1.53 |
PE (trailing) |
19.11
Below Average |
12M Dividends | 0.655 |
Last Dividend Date | 8/28/20 |
Dividend Yield | 1.73% |
Fin. Strength
Net Profit Margin | 6.9% |
Cash from Op. / Cur. Liabilities | 0.37 |
Diluted Earnings / Share | 1.98 |
ROE | 10.1% |
ROIC | 8.2% |
Price / Revenue | - |
Price / Book | - |
Price / CF | - |
Current Ratio | 1.0 |
Cur.Liabilities / Tot.Liabilities | 0.4 |
Financial Leverage | 1.15 |
in Mils USD |
rolling-year up to December
|
||||||
---|---|---|---|---|---|---|---|
Income Statement | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
Revenue |
17,477
|
16,547
|
17,784
|
16,570
|
15,455
|
15,832
|
|
Gross Profit |
5,396
|
5,155
|
6,018
|
5,616
|
5,177
|
4,996
|
|
R&D |
168
|
114
|
111
|
147
|
128
|
122
|
|
EBITDA |
3,685
|
3,731
|
2,875
|
2,898
|
2,626
|
2,824
|
|
Operating Income |
2,196
|
2,964
|
2,295
|
2,350
|
2,100
|
2,230
|
|
Net Income exc. Extra |
1,200
|
1,982
|
1,280
|
1,144
|
955
|
1,045
|
|
per Share | |||||||
Diluted avg Shares |
-
|
-
|
-
|
-
|
-
|
-
|
|
EPS exc. Extra |
1.98
|
3.23
|
2.08
|
1.87
|
1.57
|
1.73
|
|
Dividend |
0.66
|
0.63
|
0.36
|
0.44
|
0.44
|
0.53
|
|
Div. Yield (an.) |
1.78%
|
1.95%
|
0.68%
|
1.04%
|
1.05%
|
1.36%
|
|
Balance Sheet | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
Total Assets |
32,935
|
26,242
|
24,025
|
25,504
|
25,365
|
25,447
|
|
Cash, Eq & Invt ShortTerm |
1,008
|
2,146
|
978
|
709
|
550
|
634
|
|
Total Current Assets |
7,165
|
7,847
|
6,374
|
6,884
|
6,768
|
6,725
|
|
Total Non-Current Assets |
25,770
|
18,395
|
17,651
|
18,620
|
18,597
|
18,722
|
|
Intangibles |
15,444
|
12,891
|
12,787
|
13,759
|
13,863
|
13,952
|
|
Total Liabilities |
19,707
|
13,340
|
13,197
|
14,452
|
13,841
|
14,594
|
|
Total Current Liabilities |
7,007
|
6,268
|
5,300
|
5,299
|
4,149
|
3,477
|
|
Long Term Debt |
12,700
|
7,072
|
7,897
|
9,154
|
9,691
|
11,117
|
|
Shareholder equity |
11,958
|
11,758
|
9,820
|
9,978
|
9,887
|
9,443
|
|
Cash Flow | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
Cash from Operations |
2,567
|
2,062
|
2,192
|
1,932
|
1,767
|
1,861
|
|
Depreciation |
1,593
|
790
|
735
|
702
|
648
|
699
|
|
Cash from Investing |
-3,286
|
-245
|
-992
|
-1,246
|
-902
|
-2,691
|
|
Capex |
1,113
|
1,003
|
841
|
915
|
843
|
920
|
|
Cash from Financing |
-467
|
-682
|
-799
|
-520
|
-907
|
805
|
|
Stock Issued |
-584
|
10
|
-10
|
47
|
85
|
107
|
|
Debt (LT) Issued |
319
|
161
|
-308
|
-213
|
-298
|
1,233
|
|
Free Cash Flow |
3,765
|
1,551
|
1,476
|
1,876
|
1,521
|
890
|
|
Ratios | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
Net Profit Margin |
6.9%
|
12.0%
|
7.2%
|
6.9%
|
6.2%
|
6.6%
|
|
NCFO / Op.Income |
116.9%
|
69.6%
|
95.5%
|
82.2%
|
84.1%
|
83.5%
|
|
Current Ratio |
1.0
|
1.3
|
1.2
|
1.3
|
1.6
|
1.9
|
|
Financial Leverage D/E |
1.15
|
0.64
|
0.76
|
0.82
|
0.87
|
1.01
|
|
Return on Capital Avg |
8.2%
|
11.6%
|
8.6%
|
6.4%
|
6.2%
|
6.8%
|
|
Return on Shareholder Equity |
10.1%
|
18.4%
|
12.9%
|
11.5%
|
9.9%
|
11.2%
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available